Inflammatory Bowel Disease Management and Patient Outcomes

Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is managed through a combination of pharmacological, dietary, endoscopic and surgical interventions aimed at inducing and maintaining remission, promoting mucosal healing and preventing complications. Conventional therapies include aminosalicylates for mild disease, corticosteroids for induction of remission, immunomodulators such as thiopurines or methotrexate for maintenance, and biologics targeting tumour necrosis factor-α or integrins for moderate to severe cases. Treatment goals have shifted from symptomatic relief to objective measures of inflammation, notably endoscopic and histological healing, guided by treat-to-target strategies. Personalised medicine approaches—using prognostic biomarkers and molecular profiling—seek to predict disease course and optimise therapy. Nutritional interventions, including exclusive enteral nutrition and novel food-based regimens, offer non-pharmacological means to modulate the gut microbiome and reduce inflammation, especially in paediatric populations. Surgical resection and endoscopic dilatation remain crucial for stricturing or refractory disease, while management of extraintestinal manifestations and comorbidities (for example cardiovascular or psychological) contributes to holistic patient outcomes. Quality of life, work productivity and long-term risks such as colorectal neoplasia are increasingly assessed in both clinical trials and real-world cohorts. Global variations in disease burden and access to therapies underscore the need for adaptable management pathways and health-system preparedness.

Research from Nature Portfolio

High-resolution transcriptomic profiling of rectal mucosal samples from patients with active ulcerative colitis has identified a pronounced reduction in mitochondrial gene expression and function, correlating with disease severity. A subset of severity-associated gene signatures was shown to predict corticosteroid-induced remission in paediatric onset disease and also stratify response to anti-TNFα and anti-α4β7 integrin therapies in adults. Integration of transcriptome data with faecal microbiota profiling revealed shifts in microbial taxa linked to mucosal homeostasis, suggesting potential biomarkers to personalise treatment selection and accelerate drug development for nonresponders.

Inflammatory Bowel Disease Management and Patient Outcomes publication trend

The graph below shows the total number of articles in inflammatory bowel disease management and patient outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Mucosal healing: Restoration of the intestinal lining integrity, confirmed by endoscopy or histology, associated with reduced relapse rates.

Top-down therapy: Early use of biologics and immunomodulators to achieve rapid control of inflammation in high-risk patients.

Biomarker-stratified: Allocation of treatment based on measurable biological indicators predictive of disease course or therapeutic response.

Exclusive enteral nutrition (EEN): A dietary intervention using a nutritionally complete liquid formula as sole nutritional source to induce remission.

Faecal calprotectin: A protein released by activated neutrophils into the gut lumen, used as a non-invasive marker of intestinal inflammation.

References

1. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology (2019).
2. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nature Communications (2019).
3. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. The Lancet Gastroenterology & Hepatology (2024).
4. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Frontiers in Medicine (2021).
5. Treatment of Active Crohn’s Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology (2018).